Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9 inhibitors, are used to improve lipid levels with the ultimate goal of CV risk reduction. Statins dominate the dyslipidemia market owing to their good risk-benefit profile and evidence for reducing CV morbidity and mortality. However, the later-line treatment paradigm is evolving owing to the emergence of novel drug classes and more-positive outcomes data for the established agents. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated dyslipidemia patients are treated in the United States.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.